Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
Int J Colorectal Dis
; 36(12): 2637-2647, 2021 Dec.
Article
in En
| MEDLINE
| ID: mdl-34368890
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Int J Colorectal Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2021
Type:
Article
Affiliation country:
Japan